Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

By Keetch D.W.   Andriole G.L.   Ratliff T.L.   Catalona W.J.  

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men

By Kirby R.S.  

Urology, Vol. 46, Iss. 2, 1995-08 ,pp. : 182-186

Elsevier

Access to resources Recommend Favorite

Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere

By Kaplan S.A.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 784-785

Elsevier

Access to resources Recommend Favorite

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

By Boyle P.   Robertson C.   Manski R.   Padley R.J.   Roehrborn C.G.  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 717-722

Elsevier

Access to resources Recommend Favorite

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

By Hillman A.L.   Schwartz J.S.   Willian M.K.   Peskin E.   Roehrborn C.G.   Oesterling J.E.   Mason M.F.   Maurath C.J.   Deverka P.A.   Padley R.J.  

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 169-178

Elsevier

Access to resources Recommend Favorite